ClinicalTrials.gg
RecruitingNCT06384807Updated Sep 28, 2026

A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors

A Phase 1/2 interventional study of BHV-1510 and Cemiplimab in Solid Tumor, sponsored by Biohaven Therapeutics Ltd.. Recruiting at 17 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-28.

Sponsored by Biohaven Therapeutics Ltd. · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2024; still recruiting 2 years 7 months later.
Updated Sep 28, 2026Site recruiting status changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
500
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a Phase 1/2, first in human (FIH), open-label, multicenter study of BHV-1510 monotherapy and in Combination with Cemiplimab in participants with previously treated, advanced solid tumors.

Read the detailed description

This is a Phase 1/2, first in human (FIH), open-label, multicenter study of BHV-1510, a Trop-2 directed antibody-drug conjugate (ADC), in participants with previously treated, advanced solid tumors. The study comprises 2 parts: a Phase 1 Dose Escalation and a Phase 2 Dose Expansion. The Phase 1 will investigate the safety and tolerability of BHV-1510 given in monotherapy and given in combination with cemiplimab and identify one or more recommended doses for expansion (RDEs) and the maximum-tolerated dose (MTD) (if one exists). Once the RDE has been established, Phase 2 will open to investigate the preliminary efficacy of BHV-1510 in signal-finding expansion cohorts.

02

Conditions studied

  • Solid Tumor

Keywords

  • Trop2 targeting ADC
  • Antibody-drug conjugate
  • Trop2
  • ADC
03

In context

Lead sponsor

Biohaven Therapeutics Ltd. is the lead sponsor of 20 studies on the registry; 9 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Male or female participants aged ≥18 years.
  • Unresectable, incurable, locally advanced or epithelial-origin solid tumor that is to standard therapies, or has no approved standard therapies, or no approved standard therapies at its current treatment stage. If applicable to the tumor type, participants must have received platinum-based chemotherapy, standard of care immunotherapy, and standard of care targeted therapies.
  • (per 1.1).
  • (ECOG) Performance Status 0 or 1.
  • Participants have adequate hematologic, renal, liver, and coagulation function as defined by the following (blood transfusion or growth factor support is not allowed within 7 days prior to blood samples that will be used to establish eligibility):

    • ≥9 g/dL
    • >1,500/mm3; participants with known Duffy null phenotype who have absolute neutrophil count ≥1,200/mm3 may be enrolled
    • >100,000/mm3
    • ≥50 mL/min measured or estimated using the Cockcroft-Gault formula; 24-hour urine collection is allowed, but not required.
    • Total ≤1.5 × (ULN); participants with known Gilbert's syndrome who have total bilirubin level ≤3×ULN may be enrolled.
    • (AST) and alanine aminotransferase (ALT) \<2.5×ULN (or ≤5×ULN for participants with hepatic metastases)
    • Alkaline phosphatase \<2.5×ULN (or ≤5×ULN for participants with hepatic and/or bone metastases)
    • (INR) or prothrombin time (PT) ≤1.5×ULN
    • Activated partial thromboplastin time (aPTT) ≤1.5×ULN. Study participants on therapeutic doses of anticoagulation medication must have INR and/or aPTT ≤ the upper limit of the therapeutic range for intended use
  • Have recovered (ie, improvement to Grade 1 or better) from all acute toxicities from previous therapy, excluding alopecia and vitiligo.

BHV-1510 in Combination with specific inclusion criteria:

  • or cytologically documented advanced (locally, recurrent, inoperable, cannot betreated with curative intent) or metastatic cancer including Endometrial Carcinoma that is confirmed as proficient mismatch repair (pMMR)
  • received ≤ 2 prior lines of systemic anti-cancer therapy and at most one prior anti-programmed cell death protein 1 () (programmed death-ligand 1 [PD-L1]) therapy for advanced/ metastatic disease.

Key Exclusion Criteria:

  • Women who are pregnant or lactating.
  • intercurrent disease.
  • Has symptomatic or has had any radiation or surgery for brain metastases within 4 weeks of C1D1.
  • Has clinically significant corneal disease.
  • Requires supplemental oxygen for daily activities.
  • Previous treatment with a Trop-2-targeted therapy, including Trop-2 ADCs.
  • Has a medical history of interstitial lung disease (eg, noninfectious interstitial pneumonia requiring treatment, pneumonitis, pulmonary fibrosis, or severe radiation pneumonitis) or current interstitial lung disease or are suspected to have any of these diseases based on imaging at Screening.
  • Any standard cancer therapy (eg, chemotherapy, hormonal therapy, radiotherapy, immunotherapy, biologic therapy treatment) or experimental therapy within 3 weeks or 5 half-lives, whichever is shorter, prior to C1D1. The interval may be reduced to 2 weeks for bone and visceral metastasis therapy. Any major surgical procedure within 6 weeks prior to C1D1.
  • History of severe reactions to other monoclonal antibodies or either the drug substances or inactive ingredients of BHV-1510.
  • Has current or previously treated .
  • Use of OAP1B1 and OATP1B3 inhibitors within 14 days prior to starting trial.

BHV-1510 in Combination Specific Exclusion Criteria:

  • Hypersensitivity to cemiplimab or any of its or to cemiplimab per approved local labeling.
  • Experienced Grade 3 or higher immune-related AEs with prior treatment of anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4, OX 40, CD137).
  • Prior allogeneic stem cell or solid organ transplantation.
  • Patients with history of myocarditis.
  • Presence of cardiovascular disease
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
500 participants (estimated)

Study arms

  • Experimental
    BHV-1510 Monotherapy Dose Escalation

    Drug: BHV-1510

  • Experimental
    BHV-1510 in combination with Cemiplimab dose escalation

    Drug: BHV-1510 · Drug: Cemiplimab

Interventions

  • DrugBHV-1510

    BHV-1510 will be administered on Day 1 every 3 weeks

    Also known as: PBI-410, GQ1010

  • cemiplimab (350mg) will be administered as an IV infusion on Day 1 every 3 weeks

  • DrugBHV-1510

    BHV-1510 will be administered on Day 1 every 2 weeks

    Also known as: PBI-410, GQ1010

  • DrugBHV-1510

    BHV-1510 will be administered on Day 1 and Day 8 every 3 weeks

    Also known as: PBI-410, GQ1010

  • cemiplimab (350mg) will be administered as an IV infusion on Day 1 and Day 8 every 3 weeks

06

What researchers measure

Primary outcomes

  1. Phase 1: Number of patients with adverse events (AEs)

    Description: Incidence and severity of AEs, serious adverse events (SAEs) and dose limiting toxicities (DLTs). Severity of AEs will be assessed according to the NCI CTCAE v5.0. This applies to both the BHV-1510 monotherapy arm and BHV-1510 in combination with Cemiplimab arm.

    Time frame: Through study completion, estimated as an average of 47 months

  2. Phase 1: Recommended doses or schedules for expansion (RDEs) and maximum tolerated dose (MTD)

    Based on tolerability and preliminary antitumor activity. This applies to both the BHV-1510 monotherapy arm and BHV-1510 in combination with Cemiplimab arm.

    Time frame: Approximately 15 months

  3. Phase 2: Objective Response Rate (ORR) for BHV-1510 for monotherapy and in combination with cemiplimab

    Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) v 1.1.

    Time frame: Through study completion, estimated as an average of 47 months

  4. Phase 2: Number of patients with AEs for BHV-1510 for monotherapy and in combination with cemiplimab

    Incidence and severity of AEs, SAEs and DLTs. Severity of AEs will be assessed according to the NCI CTCAE v5.0

    Time frame: Through study completion, estimated as an average of 47 months

  5. Phase 2: Duration of Response (DoR) for BHV-1510 for monotherapy and in combination with cemiplimab

    Assessed by RECIST v 1.1

    Time frame: Through study completion, estimated as an average of 47 months

Secondary outcomes

  1. Phase 1 and 2: Maximum Plasma Concentration (Cmax) of BHV-1510, total antibody and payload (BHC-0080269)

    Time frame: Up to 8 timepoints, but not exceeding, 22 days in Cycles 1 and 3

  2. Phase 1 and 2: Area Under the Concentration versus time Curve from the end of infusion to the last measurable concentration (AUClast) of BHV-1510, total antibody and payload

    Time frame: Up to 8 timepoints, but not exceeding, 22 days in Cycles 1 and 3

  3. Phase 1 and 2: Area Under the Concentration versus time curve extrapolated to infinity (AUCinf) of BHV-1510, total antibody and payload

    Time frame: Up to 8 timepoints, but not exceeding, 22 days in Cycle 1

  4. Phase 1 and 2: Area under the concentration versus time curve over the dosing interval (AUCtau) of BHV-1510, total antibody and payload

    Time frame: Up to 8 timepoints, but not exceeding, 22 days in Cycles 1 and 3

  5. Phase 1 and 2: Elimination half-life (t1/2) of BHV-1510, total antibody and payload

    Time frame: Up to 8 timepoints, but not exceeding, 22 days in Cycles 1 and 3

  6. Phase 1 and 2: Trough concentration (Ctrough) of BHV-1510, total antibody and payload

    Time frame: Up to 8 timepoints, but not exceeding, 22 days in Cycles 1 and 3

  7. Phase 1 and 2: Total body clearance (CL) after IV administration or apparent total body clearance (CL/F) after SC administration of BHV-1510 and total antibody

    Time frame: Up to 8 timepoints, but not exceeding, 22 days in Cycles 1 and 3

  8. Phase 1 and 2: Percent bioavailability (%F) after SC administration of BHV-1510 and total antibody

    Time frame: Up to 8 timepoints, but not exceeding, 22 days in Cycles 1 and 3

  9. Phase 1 and 2: Volume of distribution at steady state (Vss) after IV administration or apparent volume of distribution at steady state (Vss/F) after SC administration of BHV-1510 and total antibody

    Time frame: Up to 8 timepoints, but not exceeding, 22 days in Cycles 1 and 3

  10. Phase 1: ORR

    Assessed by RECIST v 1.1. This applies to both the BHV-1510 monotherapy arm and BHV-1510 in combination with Cemiplimab arm.

    Time frame: Through study completion, estimated as an average of 47 months

  11. Phase 1: Duration of Response (DoR)

    Assessed by RECIST v 1.1. This applies to both the BHV-1510 monotherapy arm and BHV-1510 in combination with Cemiplimab arm.

    Time frame: Through study completion, estimated as an average of 47 months

  12. Phase 1 and 2: Immunogenicity of BHV-1510

    Incidence of ADA at baseline and post-treatment, including ADA titer

    Time frame: Through study completion, estimated as an average of 47 months

  13. Phase 2: Disease control rate (DCR) for BHV-1510 for monotherapy and in combination with cemiplimab

    Assessed by RECIST v 1.1

    Time frame: Through study completion, estimated as an average of 47 months

  14. Phase 2: Progression free survival (PFS) for BHV-1510 for monotherapy and in combination with cemiplimab

    Assessed by RECIST v 1.1

    Time frame: Through study completion, estimated as an average of 47 months

  15. Phase 2: Overall survival (OS) for BHV-1510 for monotherapy and in combination with cemiplimab

    OS is defined as the time period from the start of administration to death due to any cause

    Time frame: Through study completion, estimated as an average of 47 months

  16. Phase 2: Effects of BHV-1510 monotherapy and payload on the QTc interval using the Fridericia's correction method (QTcF), and on other ECG parameters (heart rate [HR], PR, and QRS interval)

    Time frame: Approximately 15 months

07

Study locations

16 of 17 sites recruiting
  • Site-113
    Duarte, California 91010, United States
    Recruiting
  • Site-112
    La Jolla, California 92093, United States
    Recruiting
  • Site-111
    Palo Alto, California 94304, United States
    Recruiting
  • Site-114
    Washington D.C., District of Columbia 20016, United States
    Recruiting
  • Site-103
    Miami, Florida 33176, United States
    Recruiting
  • Site-105
    Orlando, Florida 32827, United States
    Recruiting
  • Site-115
    Tampa, Florida 33612, United States
    Recruiting
  • Site-110
    Augusta, Georgia 30912, United States
    Recruiting
  • Site-109
    Detroit, Michigan 48201, United States
    Recruiting
  • Site-101
    St Louis, Missouri 63108, United States
    Completed

    Not enrolling at this site.

  • Site-117
    New York, New York 10021, United States
    Recruiting
  • Site-116
    Oklahoma City, Oklahoma 73117, United States
    Recruiting
  • Site-108
    Philadelphia, Pennsylvania 19107, United States
    Recruiting
  • Site-107
    Nashville, Tennessee 37203, United States
    Recruiting
  • Site-104
    Dallas, Texas 75231, United States
    Recruiting
  • Site-106
    West Valley City, Utah 84119, United States
    Recruiting
  • Site-102
    Fairfax, Virginia 22031, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2024 (actual). Primary completion is estimated for Feb 2028, 46 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 22, 2024
First posted
Apr 25, 2024
StartActual
Apr 22, 2024
Primary completionEst.
Feb 2028
CompletionEst.
Feb 2028
Last update
Sep 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
Site-101 is now Completed
Sep 28, 2026
Show all 1 update
  1. Sep 28, 2026
    Site-101 is now Completed
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06384807
Lead sponsor
Biohaven Therapeutics Ltd.
Responsible party
Sponsor
First posted
Apr 25, 2024
Start date
Apr 22, 2024
Primary completion
Feb 2028 (estimated)
Completion
Feb 2028 (estimated)
Last update
Sep 28, 2026

Study contacts

Chief Medical Officer
Contact
clinicaltrials@biohavenpharma.com
203-404-0410
Chief Medical Officer
study director · Biohaven Pharmaceuticals, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion